Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$33.27+0.77 (+2.37%)
Close on Nov 18, 2026Market cap $155.75MP/E –Yield –
Korsana Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Korsana Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$6.82M. For fiscal 2025 it was -$4.97M. The highest annual figure on record is -$3.63M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.97M | – |
| FY2024 | Dec 31, 2024 | -$3.63M | – |
| FY2023 | Dec 31, 2023 | -$12.95M | – |
| FY2022 | Dec 31, 2022 | -$18.54M | – |
| FY2021 | Dec 31, 2021 | -$55.20M | – |
| FY2020 | Dec 31, 2020 | -$81.27M | – |
| FY2019 | Dec 31, 2019 | -$125.04M | – |
| FY2018 | Dec 31, 2018 | -$115.25M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$838.00K | -266.9% |
| Q3 FY2025 | Sep 30, 2025 | -$1.01M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.67M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.46M | – |
| Q4 FY2024 | Dec 31, 2024 | $502.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.38M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.28M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.98M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.34M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$19.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.78M | – |
| Q2 FY2020 | Jun 30, 2020 | -$19.67M | – |
| Q1 FY2020 | Mar 31, 2020 | -$20.59M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.59M | – |
| Q3 FY2019 | Sep 30, 2019 | -$28.02M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.05M | – |
| Q1 FY2019 | Mar 31, 2019 | -$37.38M | – |
| Q4 FY2018 | Dec 31, 2018 | -$30.90M | – |
| Q3 FY2018 | Sep 30, 2018 | -$29.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -$29.78M | – |
| Q1 FY2018 | Mar 31, 2018 | -$25.28M | – |
See a number that looks wrong?